Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating)'s share price rose 2.3% during mid-day trading on Monday . The stock traded as high as $0.44 and last traded at $0.44. Approximately 440,574 shares were traded during mid-day trading, an increase of 11% from the average daily volume of 396,540 shares. The stock had previously closed at $0.43.
Sio Gene Therapies Stock Down 0.6 %
The firm's 50-day moving average price is $0.39 and its 200-day moving average price is $0.35.
Get
Sio Gene Therapies alerts:
Sio Gene Therapies (NASDAQ:SIOX – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.04) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Sio Gene Therapies
Large investors have recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new stake in Sio Gene Therapies during the 3rd quarter valued at $26,000. Jane Street Group LLC acquired a new stake in Sio Gene Therapies during the 2nd quarter valued at $33,000. Finally, Rubric Capital Management LP grew its holdings in Sio Gene Therapies by 16.5% during the 3rd quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock valued at $1,960,000 after purchasing an additional 988,995 shares in the last quarter.
Sio Gene Therapies Company Profile
(Get Rating)
Sio Gene Therapies, Inc is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focuses on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis, such as Tay-Sachs disease and Sandhoff disease.
Read More
- Get a free copy of the StockNews.com research report on Sio Gene Therapies (SIOX)
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating)'s share price rose 2.3% during mid-day trading on Monday . The stock traded as high as $0.44 and last traded at $0.44. Approximately 440,574 shares were traded during mid-day trading, an increase of 11% from the average daily volume of 396,540 shares. The stock had previously closed at $0.43.
Sio Gene Therapies Inc.（纳斯达克股票代码：SIOX — 获取评级）的股价在周一午盘交易中上涨了2.3％。该股的交易价格高达0.44美元，最后一次交易价格为0.44美元。午盘交易中约交易了440,574股，较平均每日交易量396,540股增长了11％。该股此前收于0.43美元。
Sio Gene Therapies Stock Down 0.6 %
The firm's 50-day moving average price is $0.39 and its 200-day moving average price is $0.35.
该公司的50天移动平均线价格为0.39美元，其200天移动平均线价格为0.35美元。
Get
Sio Gene Therapies
alerts:
Sio Gene Therapies (NASDAQ:SIOX – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.04) earnings per share (EPS) for the quarter.
Sio Gene Therapies（纳斯达克股票代码：SIOX — 获取评级）最后一次发布季度收益数据是在11月10日星期四。该公司公布了本季度每股收益（EPS）（0.04美元）。
Institutional Investors Weigh In On Sio Gene Therapies
Large investors have recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new stake in Sio Gene Therapies during the 3rd quarter valued at $26,000. Jane Street Group LLC acquired a new stake in Sio Gene Therapies during the 2nd quarter valued at $33,000. Finally, Rubric Capital Management LP grew its holdings in Sio Gene Therapies by 16.5% during the 3rd quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock valued at $1,960,000 after purchasing an additional 988,995 shares in the last quarter.
大型投资者最近增加了或减少了在该公司的股份。SVB Wealth LLC在第三季度收购了Sio Gene Therapies的新股份，价值26,000美元。Jane Street Group LLC在第二季度收购了Sio Gene Therapies的新股份，价值33,000美元。最后，Rubric Capital Management LP在第三季度将其在Sio Gene Therapies的持股量增加了16.5％。Rubric Capital Management LP在上个季度又购买了988,995股股票后，现在拥有该公司700万股股票，价值196万美元。
Sio Gene Therapies Company Profile
Sio Gene Therapies, Inc is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focuses on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis, such as Tay-Sachs disease and Sandhoff disease.
Sio Gene Therapies, Inc是一家处于临床阶段的生物制药公司，从事神经系统疾病基因疗法的收购、开发和商业化。其产品线侧重于帕金森氏病、GM1神经节苷脂病和GM2神经节苷脂症，例如泰萨克斯病和桑德霍夫病。
Read More
- Get a free copy of the StockNews.com research report on Sio Gene Therapies (SIOX)
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- 免费获取 StockNews.com 关于 Sio 基因疗法 (SIOX) 的研究报告
- 联合太平洋、诺福克南方航空进入买入区
- Pliant Therapeutics 的差距上涨了 34%：还有更多上行空间？
- 2023 年初的裁员将如何影响这5只生物技术股？
- 在飙升70％之后，Baudax Bio投资者的痛苦结束了吗？
- 火箭实验室在美国的首次发射会将股票送入平流层吗？
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Sio 基因疗法的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Sio Gene Therapies及相关公司的最新新闻和分析师评级的简明每日摘要。
